Scholarlink

Purpose <p>To evaluate the efficacy and durability of intravitreal Faricimab (Vabysmo) in patients with neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME).</p> Methods <p>A retrospective study was conducted at a tertiary ophthalmology center. Eyes with NVAMD or DME which had received previous Anti-vascular endothelial growth factor (A-VEGF) treatment before switching to Faricimab were included. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and injection intervals were recorded at baseline and follow-up visits of up to 2.5 years.</p> Results <p>A total of 192 eyes (160 with NVAMD and 32 with DME) from 155 patients were included. The mean patient age was 79.5 ± 9.6 years, with an average follow-up duration of 468.1 ± 120.4 days from baseline. In the NVAMD cohort, BCVA improved from 0.43 ± 0.33 logMAR at baseline to 0.34 ± 0.30 at 1.5 years (<i>p</i> &lt; 0.05). CST decreased significantly from a mean of 308.3 ± 65.3 Micrometers to 242.4 ± 44.8 Micrometers at two years (<i>p</i> &lt; 0.001). The mean interval between injections increased from a mean of 33.9 ± 9.6 days at baseline to 77.6 ± 42.6 days at two years, reflecting a significant extension throughout the observation period (<i>p</i> &lt; 0.001). In eyes with DME, CST declined from 403.6 ± 121.9 Micrometers at baseline to 303.2 ± 105.2 Micrometers at one year (<i>p</i> &lt; 0.001), while BCVA remained stable. Injection intervals extended from 34.4 ± 10.3 to 60.9 ± 20.5 days at one year (<i>p</i> &lt; 0.001).</p> Conclusion <p>In this study of previously treated eyes with NVAMD and DME, Faricimab demonstrated sustained anatomical and functional benefits alongside meaningful injection interval extension.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world evidence of long-term durability and efficacy of faricimab as an advanced treatment line for NVAMD and DME

  • 期刊论文

  • 发表日期：

    2025年12月23日

查看全文
  • Alon Moore Galindo,
  • Avi Ohayon,
  • Keren Hod,
  • Meira Fogel Levin,
  • Noa Geffen,
  • Shiri Shulman

摘要

Purpose

To evaluate the efficacy and durability of intravitreal Faricimab (Vabysmo) in patients with neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME).

Methods

A retrospective study was conducted at a tertiary ophthalmology center. Eyes with NVAMD or DME which had received previous Anti-vascular endothelial growth factor (A-VEGF) treatment before switching to Faricimab were included. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and injection intervals were recorded at baseline and follow-up visits of up to 2.5 years.

Results

A total of 192 eyes (160 with NVAMD and 32 with DME) from 155 patients were included. The mean patient age was 79.5 ± 9.6 years, with an average follow-up duration of 468.1 ± 120.4 days from baseline. In the NVAMD cohort, BCVA improved from 0.43 ± 0.33 logMAR at baseline to 0.34 ± 0.30 at 1.5 years (p < 0.05). CST decreased significantly from a mean of 308.3 ± 65.3 Micrometers to 242.4 ± 44.8 Micrometers at two years (p < 0.001). The mean interval between injections increased from a mean of 33.9 ± 9.6 days at baseline to 77.6 ± 42.6 days at two years, reflecting a significant extension throughout the observation period (p < 0.001). In eyes with DME, CST declined from 403.6 ± 121.9 Micrometers at baseline to 303.2 ± 105.2 Micrometers at one year (p < 0.001), while BCVA remained stable. Injection intervals extended from 34.4 ± 10.3 to 60.9 ± 20.5 days at one year (p < 0.001).

Conclusion

In this study of previously treated eyes with NVAMD and DME, Faricimab demonstrated sustained anatomical and functional benefits alongside meaningful injection interval extension.